{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:09:00Z","timestamp":1784808540315,"version":"3.55.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The use of small doses of vitamin D\n                      <jats:sub>3<\/jats:sub>\n                      analogs or metabolites is common in the prevention of renal osteodystrophy. Their use in the treatment of osteoporosis has been limited by their potent adverse effects, causing hypercalcemia and hypercalciuria. We evaluated a vitamin D\n                      <jats:sub>2<\/jats:sub>\n                      analog, i.e., 1\u03b1-hydroxyvitamin D\n                      <jats:sub>2<\/jats:sub>\n                      (doxercalciferol), that has a lower incidence of adverse effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a 1-year pilot randomized double-blind, placebo-controlled study, 55 postmenopausal women (aged 60\u201371 years) with osteopenia were treated for a year with either doxercalciferol or placebo, and 41 women completed an optional second year. The dose of 1 \u00b5g was increased by 1 \u00b5g at weekly intervals to a maximum of 5 \u00b5g. The daily dose of doxercalciferol averaged 4.1 \u00b5g after 12 months and 3.6 \u00b5g after 24 months. Bone mineral density (BMD) measurements by dual-energy X-ray absorptiometry (DEXA) of the spine and femoral neck were obtained at 6-month intervals for 24 months. The serum and urine calcium levels were measured frequently for safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the primary intention-to-treat (ITT) analysis at 12 months, there was no significant difference between the two groups for femoral neck and spine BMD. At 24 months, there was a significant difference in favor of doxercalciferol for femoral neck BMD, with the treatment\/placebo difference being 1.70% (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.047); for spine BMD, the treatment\/placebo difference was 1.1% (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.36). In the per-protocol analysis at 12 months, the doxercalciferol\/placebo difference for femoral neck was 0.5% (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.497) and for spine BMD was 1.6% (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.071). At 24 months, the doxercalciferol\/placebo difference for femoral neck BMD was 2.2% (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.017) and for spine BMD was 2.4% (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.041). Over 24 months, there were five mild hypercalcemia events, 2.54 mmol\/L (&amp;gt;10.2 mg\/dl), in five patients. The mean 24-h urine calcium increased by 3.75 mmol (150 mg), with 16 episodes of hypercalciuria, 10 mmol (&amp;gt;400 mg), in 12 patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results show that doxercalciferol treatment showed no difference from the placebo group on bone loss at 12 months; however, at 24 months, doxercalciferol showed significant prevention of bone loss from the femoral neck and spine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/<\/jats:ext-link>\n                      , identifier NCT07660536.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1640045","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:59:33Z","timestamp":1784807973000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of doxercalciferol (1\u03b1 hydroxyvitamin D2) on spine and femur bone mineral density in postmenopausal osteopenic women"],"prefix":"10.3389","volume":"17","author":[{"given":"J. C.","family":"Gallagher","sequence":"first","affiliation":[{"name":"Bone Metabolism Unit, Creighton University School Medicine","place":["Omaha, NE, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Mazess","sequence":"additional","affiliation":[{"name":"Department Medical Physics, University of Wisconsin","place":["Madison, WI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1201\/9781420019322.ch10","article-title":"Role of vitamin D-dependent and vitamin D-independent mechanisms in absorption of food calcium","volume":"81","author":"Holick","year":"1988","journal-title":"J Clin Invest"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.69.7.1673","article-title":"Control of 25-hydroxycholecalciferol metabolism by parathyroid glands","volume":"69","author":"Garabedian","year":"1972","journal-title":"Proc Natl Acad Sci USA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(70)91344-9","article-title":"Effect of age on calcium absorption","volume":"11","author":"Bullamore","year":"1970","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/65.3.790","article-title":"Serum vitamin D metabolites and calcium absorption in normal young and elderly free-living women and in women living in nursing homes","volume":"65","author":"Kinyamu","year":"1997","journal-title":"Am J Clin Nutr"},{"key":"B6","article-title":"The effect of age on serum immunoreactive parathyroid hormone in normal and osteoporotic women","volume":"85","author":"Gallagher","year":"1980","journal-title":"J Lab Clin Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650020502","article-title":"Effect of age on circulating immunoreactive and bioactive parathyroid hormone levels in women","volume":"2","author":"Forero","year":"1987","journal-title":"J Bone Miner Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.5650111005","article-title":"Effect of parathyroid hormone (hPTH (1-34) infusion on serum 1,25-dihydroxyvitamin D and parathyroid hormone in normal women","volume":"11","author":"Kinyamu","year":"1996","journal-title":"J Bone Min Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/s0300-595x(73)80045-3","article-title":"The crush fracture syndrome in postmenopausal women","volume":"2","author":"Gallagher","year":"1973","journal-title":"Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(70)91344-9","article-title":"Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: Effect of age and dietary calcium","volume":"64","author":"Gallagher","year":"1979","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/0026-0495(90)90268-h","article-title":"Metabolic effects of synthetic calcitriol (Rocaltrol) in the treatment of postmenopausal osteoporosis","volume":"39","author":"Gallagher","year":"1990","journal-title":"Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-61-3-457","article-title":"Effect of long-term treatment with calcitriol on calcium absorption and mineral metabolism in postmenopausal osteoporosis","volume":"61","author":"Riggs","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(74)93150-x","article-title":"Action of 1alpha-hydroxy vitamin D3 on calcium absorption and bone resorption in man","volume":"1","author":"Peacock","year":"1974","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/bf02064045","article-title":"The effect of a 1\u03b1-hydroxycholecalciferol and hormone therapy on the calcium balance of post-menopausal osteoporosis","volume":"22","author":"Marshall","year":"1977","journal-title":"Calcif Tissue Res (Suppl)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/bf02556211","article-title":"Calcium absorption in normal and osteoporotic post-menopausal women","volume":"49","author":"Morris","year":"1991","journal-title":"Calcif Tissue Int"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5122(88)90161-2","article-title":"Local action of oral 1,25-dihyroxycholecalciferol on calcium absorption in osteoporosis","volume":"46","author":"Francis","year":"1986","journal-title":"Am J Clin Nutr"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-017-4351-2","article-title":"Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis","volume":"29","author":"Uenishi","year":"2018","journal-title":"Osteoporosis Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(90)90270-m","article-title":"Calcitriol in the treatment of postmenopausal osteoporosis","volume":"84","author":"Aloia","year":"1988","journal-title":"Am J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-110-4-267","article-title":"Calcitriol treatment is not effective in postmenopausal osteoporosis","volume":"110","author":"Ott","year":"1989","journal-title":"Ann Intern Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-113-9-649","article-title":"Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol: A randomized controlled study","volume":"113","author":"Gallagher","year":"1990","journal-title":"Ann Intern Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/0169-6009(92)91658-6","article-title":"Treatment of postmenopausal osteoporosis with calcitriol or calcium","volume":"326","author":"Tilyard","year":"1992","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/00003086-199403000-00033","article-title":"Alfacalcidol (alpha D3) and calcium in osteoporosis","volume":"300","author":"Menczel","year":"1994","journal-title":"Clin Orthop Relat Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/bf01621900","article-title":"Long-term treatment of postmenopausal osteoporosis with active vitamin D3, 1-alpha-hydroxycholecalciferol (1 alpha-OHD3) and 1, 24 Dihydroxycholecalciferol (1, 24(OH)2D3)","volume":"32","author":"Shiraki","year":"1985","journal-title":"Endocrinol Japan"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-008-0868-y","article-title":"Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls","volume":"26","author":"O\u2019Donnell","year":"2008","journal-title":"J Bone Miner Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2011.07.011","article-title":"A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study","volume":"49","author":"Matsumoto","year":"2011","journal-title":"Bone"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2552","article-title":"A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial","volume":"90","author":"Matsumoto","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1007\/s00774-023-01470-7","article-title":"Frequency and determinants of serum calcium monitoring during eldecalcitol therapy in patients with osteoporosis","volume":"41","author":"Ri","year":"2023","journal-title":"J Bone Miner Metab"},{"key":"B28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/0886022x.2019.1578667","article-title":"Hypercalcemia and acute kidney injury induced by eldecalcitol in patients with osteoporosis: a case series of 32 patients at a single facility","volume":"41","author":"Aihara","year":"2019","journal-title":"Ren Fail"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12825","article-title":"Effect of increasing doses of vitamin D on bone mineral density and serum N-terminal telopeptide in elderly women: a randomized controlled trial","volume":"284","author":"Smith","year":"2018","journal-title":"J Intern Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/nejmoa2202106","article-title":"Supplemental vitamin D and incident fractures in midlife and older adults","volume":"387","author":"LeBoff","year":"2022","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1988.254.4.e402","article-title":"Biological activity of 1,25-dihydroxyvitamin D2 and 24-epi-1,25-dihydroxyvitamin D2","volume":"254","author":"DeLuca","year":"1988","journal-title":"Am J Physiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-178-42028","article-title":"1\u03b1-Hydroxyvitamin D2 is less toxic than 1\u03b1-hydroxyvitamin D3 in the rat","volume":"178","author":"Sjoden","year":"1985","journal-title":"Proc Soc Exp Biol Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/en.136.11.4749","article-title":"Metabolism of 1 alpha-hydroxyvitamin D2 to activated dihydroxyvitamin D 2 metabolites decreases endogenous 1 alpha, 25-dihydroxyvitamin D 3 in rats and monkeys","volume":"136","author":"Knutson","year":"1995","journal-title":"Endocrinology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650090504","article-title":"Effects of increasing doses of 1 alpha-hydroxyvitamin D2 on calcium homeostasis in postmenopausal osteopenic women","volume":"9","author":"Gallagher","year":"1994","journal-title":"J Bone Miner Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-33-6-992","article-title":"Competitive protein-binding radioassay for 25-OHD3","volume":"33","author":"Haddad","year":"1971","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-58-1-91","article-title":"A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: Application to clinical studies","volume":"58","author":"Reinhardt","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/32.11.2060","article-title":"Assay of circulating 1,25-dihydroxyvitamin D involving a novel single-cartridge extraction and purification procedure","volume":"32","author":"Hollis","year":"1986","journal-title":"Clin Chem"},{"key":"B38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/15321818208056985","article-title":"Characterization of the binding sites of anti-parathyroid hormone antisera using synthetic parathyroid hormone peptides","volume":"3","author":"Atkinson","year":"1982","journal-title":"J Immunoassay"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/0076-6879(84)07036-1","article-title":"Osteocalcin: Isolation, characterization and detection","volume":"107","author":"Gundberg","year":"1984","journal-title":"Methods Enzymol"},{"key":"B40","article-title":"Vertebral morphometry: Normative data","volume":"4","author":"Gallagher","year":"1988","journal-title":"Bone Mineral"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1021\/jo01304a022","article-title":"Direct C (1) hydroxylation of vitamin D3 and related compounds","volume":"45","author":"Paaren","year":"1980","journal-title":"J Org Chem"},{"key":"B42","article-title":"Method for preparing 1\u03b1-hydroxyvitamin D compounds","author":"DeLuca","year":"1985","journal-title":"U.S. Patent 4,554,106"},{"key":"B43","volume-title":"Analysis of messy data, vol. I, designed experiments","author":"DeLuca","year":"1984"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.534","article-title":"Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women\u2019s Health Across the Nation (SWAN)","volume":"27","author":"Greendale","year":"2012","journal-title":"J Bone Miner Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1172\/jci112462","article-title":"Rates of bone loss in the appendicular and axial skeletons of women. Evidence of substantial vertebral bone loss before menopause","volume":"77","author":"Riggs","year":"1986","journal-title":"J Clin Invest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1172\/jci113283","article-title":"Role of vitamin D-dependent and vitamin D-independent mechanisms in absorption of food calcium","volume":"81","author":"Sheikh","year":"1988","journal-title":"J Clin Invest"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s002239900269","article-title":"Effect of vitamin D receptor genotypes on calcium absorption, duodenal vitamin D receptor concentration, and serum 1,25dihydroxyvitamin D levels in normal women","volume":"60","author":"Kinyamu","year":"1997","journal-title":"Calcif Tissue Int"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1210\/jc.75.1.176","article-title":"Evidence of an age-related decrease in intestinal responsiveness to vitamin D: relationship between serum 1,25-dihydroxyvitamin D3 and intestinal vitamin D receptor concentrations in normal women","volume":"75","author":"Ebeling","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(90)90269-i","article-title":"1,25-Dihydroxyvitamin D3: Short- and long-term effects on bone and calcium metabolism in patients with postmenopausal osteoporosis","volume":"79","author":"Gallagher","year":"1982","journal-title":"Proc Natl Acad Sci USA"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1172\/jci108424","article-title":"Comparison of effects of 1alpha-hydroxy-vitamin D3 and 1,25-dihydroxy-vitamin D3 in man","volume":"57","author":"Brickman","year":"1976","journal-title":"J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/114.11.2043","article-title":"Antirachitic activity of 1 alpha-hydroxyergocalciferol and 1 alpha-hydroxycholecalciferol in rats","volume":"114","author":"Sj\u00f6den","year":"1984","journal-title":"J Nutr"},{"key":"B52","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/0304-4165(88)90145-6","article-title":"The plasma binding protein for vitamin D is a site of discrimination against vitamin D2 compounds by the chick","volume":"965","author":"DeLuca","year":"1988","journal-title":"Biochem Biophys Acta"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1126\/science.67.1744.556.a","article-title":"A comparison of vitamin D2 and D3 in New World primates. I. Production and regression of osteodystrophia fibrosa","volume":"17","author":"Hunt","year":"1967","journal-title":"Lab Anim Care"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/102.8.975","article-title":"A comparison of the toxicity of ergocalciferol and cholecalciferol in rhesus monkeys (Macaca mulatta)","volume":"102","author":"Hunt","year":"1972","journal-title":"J Nutr"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/en.2016-1139","article-title":"Differential responses to vitamin D2 and vitamin D3 are associated with variations in free 25-hydroxyvitamin D","volume":"157","author":"Chun","year":"2016","journal-title":"Endocrinology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s002239900261","article-title":"1alpha-hydroxyvitamin D2 partially dissociates between preservation of cancellous bone mass and effects on calcium homeostasis in ovariectomized rats","volume":"60","author":"Erben","year":"1997","journal-title":"Calcif Tissue Int"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1055\/a-0754-1956","article-title":"Doxercalciferol alleviates bone deteriorations and cartilage degeneration in aging mice","volume":"128","author":"Li","year":"2020","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/bf02554866","article-title":"Different actions of vitamin D2 and D3 on bone metabolism in patients treated with phenobarbitone\/phenytoin","volume":"37","author":"Tjellesen","year":"1985","journal-title":"Calcif Tissue Int"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.352","article-title":"Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism","volume":"79","author":"Weissling-Perry","year":"2011","journal-title":"Kidney Int"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1159\/000329663","article-title":"Differential effects of oral doxercalciferol (Hectorol) or paricalcitol (Zemplar) in the Cyp27b1-null mouse model of uremia","volume":"119","author":"St-Arnaud","year":"2011","journal-title":"Nephron Exp Nephrol"},{"key":"B61","article-title":"A comparison of the effects of calcitriol or calcium supplements","volume-title":"Vitamin D. a chemical, biochemical and clinical update","author":"Gallagher","year":"1985"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-066222","article-title":"Effect of active vitamin D treatment on development of type 2 diabetes: DPVD randomised controlled trial in Japanese population","volume":"377","author":"Kawahara","year":"2022","journal-title":"BMJ"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1574679","article-title":"Efficacy and safety of intermittent intravenous doxercalciferol in the treatment of secondary hyperparathyroidism in Chinese patients on maintenance hemodialysis: a phase II, open-label, prospective, multicenter study","volume":"16","author":"Yang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.bone.2019.07.026","article-title":"Vitamin D sterols increase FGF23 expression by stimulating osteoblast and osteocyte maturation in CKD bone","volume":"127","author":"Pereira","year":"2019","journal-title":"Bone"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2025.06.015","article-title":"Inhibition of WAC alleviates the chondrocyte proinflammatory secretory phenotype and cartilage degradation via H2BK120ub1 and H3K27me3 coregulation","volume":"15","author":"Xu","year":"2025","journal-title":"Acta Pharm Sin B"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1640045\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:59:35Z","timestamp":1784807975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1640045\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":65,"alternative-id":["10.3389\/fendo.2026.1640045"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1640045","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"1640045"}}